AgroAmerica Presents Its 2022 Sustainability Report: A Future Built to Last
18.7.2023 17:12:00 EEST | Business Wire | Press release
AgroAmerica presented its ninth Sustainability Report. This report provides an updated overview of the performance of the company’s banana division and the achievements made in 2022 through its Corporate Sustainability Strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717281841/en/
AgroAmerica's sustainability report details the structure, governance, strategy, and management of the company, with a specific focus on the material issues identified. Over the past year, AgroAmerica has worked on environmental, social, and governance topics that are relevant to the business. (Photo: Business Wire)
"We are pleased to announce that the year 2022 marks the final chapter of our current strategy, as well as the starting point of a significant transformation. In this process, our strong foundation in sustainability will drive a new robust integrated strategy that will shape our path in 2023-24. This exciting step will lead us to continuous improvement and a more sustainable future," explained Fernando Bolaños, CEO of AgroAmerica.
Using a regenerative approach, the company undertakes actions aimed at promoting soil health, resource conservation, biodiversity preservation, and the reduction of carbon emissions. As part of this strategy, AgroAmerica has initiated a project, unique in the region, that protects bees and other pollinators in forest conservation areas located in our operations.
Some of the highlighted achievements included in this report:
- The installation of a macro sanctuary to house and protect more than 30,000 native bees and pollinators.
- Receiving the "2022 Conservation Leadership Award" from the RSPO Excellence Awards to the Mayan Biosphere conservation project.
- Receiving the "Grand Prize in Business Sustainability" from the American Chamber of Commerce for our "Mangrove Ecosystem Restoration Project" on the Pacific Coast of Guatemala.
- Obtaining the “RSPO certification” in our operations in Panama, meaning that all the operations of the tropical oil division in AgroAmerica are now certified.
- The generation of over 12,000 direct and indirect jobs that promote gender equality and development opportunities for our employees, their families and our neighboring communities.
- Contributing to 11 of the United Nations’ Sustainable Development Goals.
- Holding 11 international certifications related to good practices, sustainable operations, and food quality and safety.
- The conservation of more than 970 hectares of forests in areas within our company’s operations.
"We are a world-class corporation that adapts to global market challenges to exceed environmental, governance and social expectations and offer high-value-added products to the world," stated Javier Aguirre, Corporate Director.
This report shows our path forward with a renewed focus on sustainability, and reaffirms our company's commitment to the environment, society, and governance in the production of high-quality sustainable food.
See full report here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230717281841/en/
Contact information
Susana Perez
Communications and Public Relations Coordinator
sperez@agroamerica.com
(+502) 5554-8774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom